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Amiodarone is a potent antiarrhythmic agent that is
effective in controlling both atrial and ventricular ar-
rhythmias. Recently, intravenous administration was
demonstrated to be effective in the acute management
of rhythm disorders and, in addition, appeared to
shorten the loading period normally required for oral
drug administration. This investigation examined the
hemodynamic effects of amiodarone after both acute in-
travenous bolus and continuous intravenous adminis-
tration. Patients with a left ventricular ejection fraction
greater than 0.35experienced improvedcardiac perform-
Amiodarone, a type III antiarrhythmic agent, has been dem-
onstrated to be highly effective in the management of
chronic refractory atrial and ventricular arrhythmias . The
drug's uniquely prolonged half-life of 28 days (1) results in
convenient long-term drug maintenance , but the lengthy
initial oral drug loading limits its usefulness in long-term
arrhythmia management and also necessitates lengthy and
costly hospitalization. Intravenous amiodarone has recently
been demonstrated (2,3) to be acutely effective in control-
ling refractory arrhythmias. Intravenous administration of
amiodarone could potentially shorten the loading period du-
ration and extend the drug's indications to include the man-
agement of patients in acutely unstable condition, assuming
the drug is hemodynamically weIl tolerated. This study ex-
amines the hemodynamic effect s of intravenous amiodarone
in a broad spectrum of patients , including those with sig-
nificantly compromised left ventricular function after both
acute intravenous bolus administration and 3 to 5 days of
continuous intravenous infusion.
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ance due to both acute and chronic peripheral vasodi-
lation. However, patients with a lower ejection fraction
developed a 20% decrease in cardiac index and clinically
significant elevation of right heart pressures after acute
bolus administration; these changes were variably com-
pensated for by peripheral vasodilation when the drug
was administered intravenously over 3 to 5 days contin-
uously. Therefore, intravenous amiodarone can result
in significant impairment of left ventricular performance
in patients with preexisting left ventricular dysfunction.
Methods
Study patients. The study group comprised 12 patients
with drug-resistant arrhythmias (I patient with atrial flutter
and 11 patients with ventricular tachycardia or ventricular
fibrillation). All patients signed a written consent form that
had been approved by the Investigational Review Board of
the New England Deaconess Hospital.
Among the 12 patients (10 men and 2 women), 1 had
mitral valve prolapse, presyncope and long runs (>30 beats)
of nonsustained ventricular tachycardia; 1 had idiopathic
dilated cardiomyopathy, presyncope and nonsustained ven-
tricular tachycardia; 1 had recurrent atrial flutter and 9 had
coronary artery disease, including 6 with sustained ventric-
ular tachycardia and 3 with ventricular fibrillation. In all 12
patients, at least two standard antiarrhythmic agents had
failed to control the arrhythmia as assessed by either clinical
recurrence or persistence of electrophysiologic induction of
arrhythmia despite adequate drug serum levels .
Protocol. All patients underwent fluoroscopic-guided
right heart catheterization using balloon-tipped catheters
with measurement of pulmonary capillary wedge , pulmo-
nary artery , right ventricular and right atrial pressures .
Hewlett-Packard strain gauge s were zeroed at the level of
one-half the anteroposterior chest wall diameter. Cardiac
output was determined by the Fick method using measured
oxygen consumption. Radionuclide left ventricular ejection
fraction was measured by gated blood pool scan in the left
anterior oblique projection in all patients. Arterial pressure
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was measured using a mercury sphygmomanometer, with
mean arterial pressure being one-third the diastolic and sys-
tolic measurements.
Fifteen minutes after instrumentation, a single set of con-
trol measurements were obtained followed by an intravenous
bolus injection of amiodarone (Cordarone), 300 mg, which
was administered over 5 minutes. Repeat right heart pres-
sures, oxygen consumption, radionuclide-determined left
ventricular ejection fraction and arterial pressures were mea-
sured. Patients then received a continuous intravenous in-
fusion of amiodarone, 1,000 mg, over 24 hours for 3 to 5
days, with subsequent repeat measurement of right heart
pressures, oxygen consumption, radionuclide left ventric-
ular ejection fraction and arterial blood pressure. All rea-
sonable attempts were made to maintain cardiac medications
unchanged during the infusion period with adjustments in
diuretic requirements being dictated only by marked changes
in clinical hemodynamic status. After intravenous admin-
istration of amiodarone, long-term oral amiodarone main-
tenance therapy was instituted in all patients.
All data were analyzed statistically using the paired Stu-
dent's t test.
Results
Hemodynamic profile (Table 1). The study patients
were separated into two groups consisting of those with a
left ventricular ejection fraction at rest greater than 0.35
(group A, n = 4) and those with an ejection fraction less
than 0.35 (group B, n = 8). No patient had hemodynam-
ically significant mitral regurgitation. The mean ejection
fraction for group A was 0.60, whereas the mean ejection
fraction for group B was 0.19. As expected, the patients in
group B had higher rest pulmonary capillary wedge (13
versus 4 mm Hg) and mean pulmonary artery pressures (24
versus 10 mm Hg). The rest cardiac index was 2.1 liter/
min per rrr' in group Band 2.4 liters/min per rrr' in group
A.
Hemodynamic response to intravenous amiodarone.
Group A (Table 1). After acute bolus administration of 300
mg amiodarone, cardiac index increased from 2.4 to 2.7
liters/min per rrr' and was associated with a decrease in
systemic vascular resistance from 1,721 to 1,1419
dynes . s . em - 5. Despite the increase in forward cardiac
output, pulmonary capillary wedge pressure increased from
4 to 8 mm Hg and mean pulmonary artery pressure increased
from 10 to 17 mm Hg. No significant change was noted in
either radionuclide left ventricular ejection fraction or heart
rate after bolus administration.
Continuous intravenous amiodarone administration for
3 to 5 days resulted in a further augmentation of cardiac
index to 3.4 liters/min per m2 and a further reduction in
systemic vascular resistance to I, 135 dynes-s-cm- 5 (Figure
I). Unlike acute administration, chronic intravenous therapy
resulted in a return of both pulmonary capillary wedge and
mean pulmonary artery pressures to control values. No sig-
nificant change in radionuclide left ventricular ejection frac-
ture, heart rate or right atrial pressure occurred with chronic
therapy.
Group B (Table 1). Intravenous bolus administration of
300 mg amiodarone resulted in a significant decrease in
cardiac index from 2.1 to 1.7 liters/min per m2. Despite a
significant decrease in mean arterial pressure, overall sys-
temic vascular resistance increased from 2,040 to 2,204
dynes-s-cm - 5. Mean pulmonary artery pressure increased
significantly after acute drug administration (24 to 35 mm
Hg). Although pulmonary capillary wedge pressure in-
creased from 13 to 20 mm Hg, this did not reach statistical
significance. Radionuclide left ventricular ejection fraction
and heart rate did not change significantly after drug ad-
ministration.
After continuous infusion ofamiodarone, 1,000 mg, daily
for 3 to 5 days, repeat hemodynamic variables were mea-
sured. This revealed a substantial increase in the cardiac
index to 2.3 liters/min per rrr', which was associated with
a decrease in the systemic vascular resistance to 1,770
dynes-s-cm - 5 (Fig. I). Despite the improvement in cardiac
index, there was no change in pulmonary capillary wedge
(20 mm Hg), mean pulmonary artery (30 mm Hg) or mean
right atrial (8 mm Hg) pressures. Heart rate, mean arterial
pressure and radionuclide-determined left ventricular ejec-
tion fraction also did not change significantly.
Clinical response to intravenous amiodarone. No pa-
tients in group A experienced an adverse effect during either
acute or chronic amiodarone infusion. However, five of
eight patients in group B experienced clinically significant
hemodynamic deterioration with intravenous amiodarone.
Patient 9 developed hypotension secondary to decreased
cardiac output after the 300 mg bolus infusion. The hypo-
tension resolved within 15 minutes with the use oflow doses
of dopamine. The patient subsequently received chronic
intravenous amiodarone infusions without adverse sequelae.
Patient 10 developed moderate hypotension after the intra-
venous bolus administration and then progressively devel-
oped pulmonary edema after 36 hours of continuous intra-
venous infusion that required combined dopamine and di-
uretic drugs for stabilization. The intravenous infusion was
discontinued and the patient was subsequently treated with
oral amiodarone (1,000 mg orally for 14 days) without fur-
ther incident. Patient 12 developed marked systemic hy-
potension and elevation of right heart pressures because of
decreased cardiac output that responded to dopamine in-
fusion. He then experienced a "flush" reaction to the drug
and intravenous therapy was abandoned. The other two pa-
tients (Cases 5 and 7) both developed marked pulmonary
congestion while receiving continuous amiodarone infusion.
In both patients, the congestive heart failure was treated
with vigorous diuresis and the infusion was continued for
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Table I. Hemodynamic Response of Acute and Continuous Amiodarone in 12 Patients
Pulmonary Mean Mean
Mean Systemic Capillary Pulmonary Right
Cardiac Arterial Vascular Wedge Artery Atrial
Ejection Index Pressure Resistance Pressure Pressure Pressure
Cas,: Fraction (liters/min per rrr') (mm Hg) (dynes-s-cm") (mm Hg) (mmHg) (mmHg)
Group A
Control 0.37 2.2 115 1,876 2 8 0
Acute 2.7 99 1,298 4 12 0
Chronic 3.1 92 1,067 I 9 0
2 Control 0.84 2.3 100 1,536 10 15 4
Acute 2.2 103 1,616 12 19 4
Chronic 3.4 100 1,070 4 12 I
3 Control 0.59 2.7 103 1,753 I 7 0
Acute 3.2 99 1,343 8 20 5
Chronic 3.7 103 1,268 I 9 0
4 Control 0.60 2.4 106 1,722 4 10 I
Acute 2.7 100 1,419 8 17 3
Chronic 3.4 98 1,135 2 10 0
Mean c: SD Control 0.60 2.4 :!: 0.2 106 :!: 6 1,721 :!: 140 4 :!: 4 10 :!: 4 I :!: 2
Acute 2.7 :!: 0.4+ 100 :!: 2 1,419 :!: 141 8 :!: 3* 17 :!: 4 3 :!: 2
Chronic 3.4 :!: 0.2* 98 :!: 5 1,135 :!: 94t 2 :!: 1* 10 :!: I o :!: I
Group B
5 Control 0.10 3.2 88 992 II 25 0
Acute 2.5 87 1,229 18 32 I
Chronic 3.2 91 958 20 40 6
6 Control 0.06 2.2 67 1,260 25 38 4
Acute 2.2 57 1,087 28 45 4
Chronic 2.6 77 1,287 28 30 3
7 Control 0.26 2.7 121 2,251 4 14 0
Acute 2.3 118 2,600 26 42 I
Chronic 3.0 113 1,787 16 24 8
8 Control 0.34 1.5 87 2,090 25 30 6
Acute 1.2 80 2,163 13 30 7
Chronic 1.2 87 2,062 30 45 20
9 Control 0.29 1.3 85 2,467 23 33 9
Acute l.l 73 2,611 25 38 11
Chronic 2.0 99 2,148 15 22 5
10 Control 0.18 1.6 79 1,622 12 30 6
Acute l.l 67 1,800 25 40 13
Chronic
11 Control 0.10 1.0 110 4,038 1 8 4
Acute 1.0 101 3,960 4 18 2
Chronic 1.8 110 2,378 10 16 3
1~ Control 0.20 2.9 93 1,600 2 10 I
Acute 2.0 84 2,186 23 33 2
Chronic
Mean ± SD Control 0.19 2.1 :!: 0.8 91 :!: 17 2,040 :!: 948 13 :!: 10 24 :!: II 4 :!: 3
Acute 1.7 :!: 0.6t 83 :!: 19+ 2,204 :!: 908 20 :!: 8 35 :!: 9+ 5 :!: 5
Chronic 2.3 :!: 0.8t 96 :!: 14 1,770 :!: 546 20:!: 8 30 :!: II 8 :!: 6
*p < 0.05; tp < 0.01; +p < 0.001.
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Discussion
Clinical efficacy. Amiodarone is a highly effective an-
tiarrhythmic agent that has demonstrated clinical effective-
ness when other agents have failed . Many inve stigators
(1,4-9) have demonstrated clinical suppression of refractory
arrhythmias by amiodarone in 60 to 90% of patients studied .
Although the drug was initially considered to have few side
effects (4,8) , more recent reports (9-11) have demonstrated
significant problems , with the most worrisome being pul-
monary infiltrates, neurologic abnormalities, skin discol-
oration and thyroid disturbances. Exacerbation of congestive
heart failure has been relatively infrequent with the oral
preparation, but the extremely long half-life of 15 to 30
days has limited the utility of sequential hemodynamic mea-
surements to accurately assess its hemodynamic effects.
Preliminary studies (4) have suggested that intravenous
amiodarone results in a rapid antiarrhythmic effect which
lasts from 20 minutes to 4 hours and which can be utilized
to control refractory ventricular arrhythmias. Several in-
vestigators (12-14) have collectively reported selective re-
version of ventricular tachycardia to sinus rhythm with in-
travenous amiodarone in 11 patients without significant side
effects.
Morady et al. (3) confirmed the therapeutic effectiveness
of intravenous amiodarone in 12 of 15 patients with ven-
tricular tachycardia refractory to at least two conventional
antiarrhythmic drugs . Control was obtained within 12 hours
in all successfully treated patients and intravenous usage
did not result in exacerbation of congestive heart failure in
any patient despite a group mean ejection fraction of 0.30 .
Adverse hemodynamic effects. Although intravenous
amiodarone has major value as an antiarrhythmic agent to
control acute life-threatening arrhythmias, it has also been
reported to have significant side effects. Both hypotension
and cardiac collapse are the major complications reported
with intravenous usage. Benaim and Uzan (12) reported that
five of their patients after intravenous amiodarone admin-
istration experienced cardiovascular collapse and required
vasopressor agents. Michat et al. (14) noted a mean decrease
in blood pressure of 15 mm Hg in 6 of 20 patients , although
no severe complications ensued . Installe et al. (15) admin-
istered intravenous amiodarone to 95 patients with ar-
rhythmia after cardiac operation s. Seventeen patients (18%)
experienced an average decrease in mean arterial pressure
of 15 mm Hg and five patients with marked cardiomegaly
developed cardiogenic shock requiring vasopressors and
intraaortic balloon pulsation . Lastly, 11 cases of adverse
effects of intravenous amiodarone were reported to the French
Society of Cardiology (16) , including five deaths after bolus
administration to patients with significant left ventricular
dysfunction.
Therefore, adverse hemodyn amic effects of intravenous
amiodarone appear to represent the major complication lim-
iting its clinical usefulness. Singh ct al. (17) examined the
effects of amiodarone on cardiac and coronary hemody-
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the full 5 days with increased doses of diuretic drugs being
necessary. All five patients are now receiving long-term oral
amiodarone and have not experienced either recurrence of
arrhythmia or exacerbation of congestive heart failure.
cbronic:
Figure 1. Effect of acute and continuous intravenou s amiodarone
in patients in group A (X--X) and group B (e----e) on
cardiac index (liters/min per m-), systemic vascular resistance
(dynes-s-crn: ") and mean pulmonary artery pressure (mm Hg). *p
< 0.05 ; **p < 0.01 ; ***p < 0.001 .
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namics in open chest dogs. When administered in concen-
trations between 2.5 to 10 rug/kg, amiodarone produced a
dose-related decrease in both coronary and systemic vas-
cular resistance, as well as a decrease in cardiac contractile
force and first derivative of left ventricular pressure (dP/dt).
Both cardiac output and coronary blood flow increases offset
the mild negative inotropic effect. Similar results were re-
ported by Cote et al. (18) in 16 patients who received 5 mgt
kg of intravenous amiodarone at the time of cardiac cath-
eterization. Acute intravenous administration of amiodarone
resulted in increased coronary sinus blood flow, increased
cardiac index (2.9 to 3.3 liters/min per m2) and decreased
systemic vascular resistance. Cote et al. (18) concluded that
the drug is a potent vasodilator with excellent afterload-
reducing properties. However, their study probably ex-
cluded patients with impaired left ventricular function be-
cause only 8 of the 16 patients had an elevated left ven-
tricular end-dia stolic pressure .
Acute and chronic hemodynamic effects in the study
patients. Our 12 patients with refractory arrhythmias man-
ifested greater left ventricular dysfunction, with 8 of the 12
having a left ventricular ejection fraction less than 0.35 .
The hemodynamic effects of intravenous amiodarone were
determ ined immediatel y after intravenous bolus administra-
tion and also after chronic (3 to 5 days) infusion. Patients
with good left ventricular function (group A) (Fig. l A)
exhibited an increase in cardiac index and a decrease in
systemic vascular resistance after both acute and chronic
administration consistent with the drug ' s known potent vas-
odilator properties. Of note is the mild increase in both
pulmonary capillary wedge and mean pulmonary artery
pressures, possibly reflecting a mild negative inotropic ef-
fect that is compensated for chronically by further systemic
vasodilation. The response of patients in group B (left ven-
tricular ejection fraction <0.35) to acute and chronic intra-
venous amiodarone was quite different (Fig. IB). A 20%
reduction in cardiac index occurred with bolus injection and
was associated with an increase in mean pulmonary artery
pressure and systemic vascular resistance . This is consistent
with a negative inotropic effect which reduces cardiac output
and mean arterial pressure , resulting in activation of sym-
pathetic peripheral vasoconstriction and, hence, negating
the inherent peripheral vasodilation of the drug. After chronic
intravenous therapy, there was a gradual return to control
values which is due to a decrease in the systemic vascular
resistance . Continuous infusion results in more pronounced
systemic vasodilation, which is able to compensate for the
negative inotropic effect. The hemodynamic effects are due
to the drug alone since the diluent (Tween 80) has no known
hemodynamic effect.
Intravenous amiodarone possesses both negative ino-
tropic and peripheral vasodilatory properties. In patients
with good left ventricular function, the negative inotropic
properties are minimal because of the intrinsic cardiac con-
tractile reserve. However, patients with moderately im-
paired left ventricular function are much more vulnerable
to the adverse contractile effects . The clinical potential of
this adverse effect on left ventricular performance is high-
lighted by five of the eight patients with left ventricular
ejection fraction less than 0 .35 who developed a major clin-
ical deterioration consisting of either marked hypotension
(three patients) or severe worsening of left heart failure (two
patients). The deterioration occurred during bolus admin-
istration in two patients and during continuous infusion in
three patients .
A more gradual intravenous administration of amioda-
rone may have avoided the acute hypotension seen with
bolus administration, but presumably it would not avoid the
exacerbation of left ventricular failure which occurred in
three patients receiving a constant intravenous infusion. De-
spite the adverse hemodynamic effects, all rut two patients
were continued on intravenous therapy by increasing di-
uretic dosage. Two patients developed hypotension and pul-
monary edema that did not respond promptly to vasopressors
and necessitated discontinuation of intravenous drug
therapy.
All patients have received long-term oral therapy without
significant adverse hemod ynamic effects. The experience
that oral amiodarone is well tolerated in patients with severe
left ventricu 'ar dysfunction , whereas intravenous medica-
tion is not, possibly reflects the higher serum levels obtained
with intravenous administration.
Clinical implications. The following clinical recom-
mendations are warranted: 1) intravenous amiodarone re-
sults in both negative inotropic and peripheral vasodilatory
effects; 2) intravenous amiodarone should be reserved as a
second or third line antiarrhythmic agent in patients with
moderate left ventricular dysfunction because of its adverse
hemodynamic effects; 3) careful hemodynamic monitoring
is warranted in patients with impa ired left ventricular func-
tion who are receiving intravenous amiodarone; and 4) rapid
intravenous bolus admini stration of amiodarone is rarely
appropriate , and a more gradual intravenous load over 30
to 60 minutes may avoid the hypoten sion of the 5 minute
injection ; and 5) those patient s with chronic ventricular ar-
rhythmias are best treated with the safer, albeit longer ,
method of high dose oral loading .
We are grateful for the techni cal assistance of the cardiac catheterization
laboratory personnel and the secretarial assistance of Elizabeth Leach and
Janice Owen .
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